You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
日本药业巨擘参战新冠药物开发 盐野义展开临床试验
阿思达克 07-26 12:05
据《华尔街日报》报道,继辉瑞(PFE.US)及默克(MRK.US)展开新冠肺炎治疗方法开发後,日本盐野义制药已於本月展开对首款每日只需服用一次的新冠肺炎药片进行临床试验,试验可能持续到明年。

盐野义制药比辉瑞和默克公司晚了几个月,後两者已经开始对新冠药物进行中後期试验。辉瑞表示,该公司每日服用两次的药片可能最快今年可投入市场。该公司正准备招募2,000多名患者,进行该抗病毒药物与一款作为增强剂的抗病毒药物联合使用的试验,使用安慰剂做为对照组。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account